Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 8/20 | 0.60 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17130415 | 0.77 | MAP4K4 (0.62) | MAP4K4PIK3CAPDE10AEGFRKDR | |
| SCHEMBL867042 | 0.75 | MAP4K4 (0.60) | MAP4K4PIK3CAPDE10AEGFRKDR | |
| SCHEMBL14044627 | 0.75 | MAP4K4 (0.60) | MAP4K4PIK3CAPDE10AEGFRKDR | |
| SCHEMBL58274 | 0.75 | MAP4K4 (1.00) | MAP4K4PIK3CAPDE10AEGFRKDR | |
| SCHEMBL4818798 | 0.75 | MAP4K4 (0.60) | MAP4K4PIK3CAPDE10AEGFRKDR | |
| SCHEMBL25776743 | 0.75 | MAP4K4 (0.60) | MAP4K4PIK3CAPDE10AEGFRKDR | |
| Hydrochloric Acid SCHEMBL15019896 | 0.73 | MAP4K4 (0.96) | MAP4K4PIK3CAPDE10AEGFRKDR | |
| Hydrochloric Acid SCHEMBL30590600 | 0.73 | MAP4K4 (0.96) | MAP4K4PIK3CAPDE10AEGFRKDR | |
| Iodide SCHEMBL30111106 | 0.73 | MAP4K4 (0.96) | MAP4K4PIK3CAPDE10AEGFRKDR | |
| SCHEMBL1811759 | 0.72 | AXL (0.52) | MAP4K4PIK3CAPDE10AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111233869-B | Novel compound for preparing Rudexilvir key intermediate and preparation method thereof | 杭州新博思生物医药有限公司 | 2022-09-16 | — | — | CN | disclosed |
| EP-2396315-B1 | QUINOLINE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-08-31 | — | — | EP | disclosed |
| US-8957090-B2 | Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2015-02-17 | — | — | US | disclosed |
| EP-2499126-B1 | FUSED BICYCLIC PYRIDINE AND PYRAZINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2015-01-07 | — | — | EP | disclosed |
| US-8513284-B2 | Fused pyridine and pyrazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20130165445-A1 | Aurora Kinase Modulators and Method of Use | AMGEN INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8404694-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20130012515-A1 | Fused Bicyclic Pyridine and Pyrazine Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2013-01-10 | — | — | US | disclosed |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-03-29 | — | — | US | disclosed |
| US-20110065709-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-20060004007-A1 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-6982265-B1 | Pyrrolotriazine inhibitors of kinases | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-01-03 | — | — | US | disclosed |
| US-20040229877-A1 | Methods of treating p38 kinase-associated conditions with pyrrolotriazine compounds | LEFTHERIS KATERINA (US) | 2004-11-18 | — | — | US | disclosed |
| US-6670357-B2 | Antiinflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-30 | — | — | US | disclosed |
| EP-1363910-A2 | METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030069244-A1 | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-10 | — | — | US | disclosed |
| EP-1183033-A4 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL MYERS SQUIBB CO (US) | 2002-07-17 | — | — | EP | disclosed |
| WO-2002040486-A2 | METHODS OF TREATING p38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-05-23 | — | — | WO | disclosed |
| EP-1183033-A1 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000071129-A1 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069244-A1 | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors | MAPK1, MAPK3, MAPK6 | MAP4K4 51/4885PIK3CA 820/4885PDE10A 3212/4885 |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | PDPK1, PDXK, PIK3CA | MAP4K4 34/4885PIK3CA 3/4885PDE10A 1743/4885 |
| US-20130012515-A1 | Fused Bicyclic Pyridine and Pyrazine Derivatives as Kinase Inhibitors | MAP3K13, MAP3K15, MAP3K12 | MAP4K4 34/4885PIK3CA 260/4885PDE10A 1943/4885 |
| US-20110065709-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, AURKB | MAP4K4 224/4885PIK3CA 98/4885PDE10A 3870/4885 |
| US-20060004007-A1 | Pyrrolotriazine inhibitors of kinases | FGFR1, FGFR2, ERBB2 | MAP4K4 293/4885PIK3CA 108/4885PDE10A 4416/4885 |
| US-20130165445-A1 | Aurora Kinase Modulators and Method of Use | AURKC, AURKA, AURKB | MAP4K4 224/4885PIK3CA 98/4885PDE10A 3870/4885 |
| US-20040229877-A1 | Methods of treating p38 kinase-associated conditions with pyrrolotriazine compounds | MAPK1, MAPK6, MAPK3 | MAP4K4 39/4885PIK3CA 893/4885PDE10A 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.